BDI Pharma Employees Raise Funds, Awareness on World Hemophilia Day

BDI Pharma Employees Raise Funds, Awareness on World Hemophilia Day
0
(0)

In recognition of the World Hemophilia DayBDI Pharma employees company-wide united to raise awareness and money to support those affected by bleeding disorders.

Events were held April 17 at the company’s South Carolina, Texas and Kansas sites, with employees joining remotely to raise money to support the WFH (World Federation of Hemophilia) by wearing custom designed red T-shirts.

BDI Pharma is donating all the funds raised during its event to the WFH, a global network of healthcare providers, national hemophilia associations, people with hemophilia and their families.

The donations will be used to support the training of healthcare professionals in making early diagnoses of bleeding disorders, as well as to provide educational programs for patients with hemophilia and their caregivers.

BDI Pharma creates customized solutions to meet the distribution and support needs of manufacturers, healthcare providers and patients. For more than two decades, the company has been serving the hemophilia community, providing solutions to healthcare providers to have access to coagulation therapies and also to the high-touch services required to assist this patient population. It is an authorized distributor of record for hemophilia factors, I.G. products, albumin, vaccines and antivenom, oncology products, supportive care, IV antibiotics, oral therapies and neurology products.

And while the effectiveness of clotting factor replacement therapy (the basic treatment to stop or prevent bleeding in people with hemophilia A and B) is a reality, people with hemophilia face everyday challenges dealing with specialty pharmaceuticals.

“As a rare disease company with a core competency in hemophilia, our involvement in this community, globally and domestically, has been both rewarding and enlightening,” Rich Gaton, co-founder and president of BDI Pharma said in a press release. “We have come to understand the impact that can be made in the lives of those affected by bleeding disorders and their families. Hemophilia can be a debilitating disease, but thanks to improvements in treatment, those people affected often can live very fulfilling lives.”

“Cost, reimbursement, availability and patient support services are just a few of the many challenges faced by those living with or affected by bleeding disorders,” Edward Stiefel, co-founder and president of BDI Pharma, said. “With this realization, we have created a portfolio of services geared towards helping manufacturers, healthcare providers and, most importantly, patients navigate the many issues that arise throughout a lifetime of treatment.”

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
×
Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
Latest Posts
  • cell therapy study
  • acquired hemophilia A treatment
  • hemophilia services for members
  • uniQure new patents

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?